Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

141. Atrial fibrillation as a risk factor for cognitive decline and dementia

Atrial fibrillation as a risk factor for cognitive decline and dementia 28460139 2017 05 01 2017 05 01 1522-9645 2017 Apr 29 European heart journal Eur. Heart J. Atrial fibrillation as a risk factor for cognitive decline and dementia. 10.1093/eurheartj/ehx208 To assess whether AF is a risk factor for cognitive dysfunction we used prospective data on AF, repeat cognitive scores, and dementia incidence in adults followed over 45 to 85 years. Data are drawn from the Whitehall II study, N = 10 308 (...) at study recruitment in 1985. A battery of cognitive tests was administered four times (1997-2013) to 7428 participants (414 cases of AF), aged 45-69 years in 1997. Compared with AF-free participants, those with longer exposure to AF (5, 10, or 15 years) experienced faster cognitive decline after adjustment for sociodemographic, behavioural, and chronic diseases (P for trend = 0.01). Incident stroke or coronary heart disease individually did not explain the excess cognitive decline; however

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

142. CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines

CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines CHAD65 and CHA2DS2-VASc Risk (...) Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines Published on: May 12, 2017 Project Number: RC0883-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of the CHAD65 and CHA2DS2-VASc risk stratification tools to determine the need for pharmacological treatment in patients with atrial fibrillation? What are the evidence-based guidelines

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

143. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials

Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials 28426886 2017 04 20 2017 04 20 1522-9645 38 10 2017 Mar 07 European heart journal Eur. Heart J. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. 742-750 10.1093/eurheartj/ehw509 The incidence and predictors (...) of stroke in patients with heart failure and preserved ejection fraction (HF-PEF), but without atrial fibrillation (AF), are unknown. We described the incidence of stroke in HF-PEF patients with and without AF and predictors of stroke in those without AF. We pooled data from the CHARM-Preserved and I-Preserve trials. Using Cox regression, we derived a model for stroke in patients without AF in this cohort and compared its performance with a published model in heart failure patients with reduced ejection

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

144. Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation

Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation 28359513 2017 03 31 2017 04 06 1558-3597 69 13 2017 Apr 04 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. 1683-1691 S0735-1097(17)30386-8 10.1016/j.jacc.2017.01.032 The safety and efficacy of aerobic exercise in heart failure (HF) patients with atrial fibrillation (AF) has not been well evaluated. This study (...) examined whether outcomes with exercise training in HF vary according to AF status. HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized 2,331 ambulatory HF patients with ejection fraction ≤35% to exercise training or usual care. We examined clinical characteristics and outcomes (mortality/hospitalization) by baseline AF status (past history of AF or AF on baseline electrocardiogram vs. no AF) using adjusted Cox models and explored an interaction

EvidenceUpdates2017

145. The future of atrial fibrillation management: integrated care and stratified therapy.

The future of atrial fibrillation management: integrated care and stratified therapy. Atrial fibrillation is one of the major cardiovascular health problems: it is a common, chronic condition, affecting 2-3% of the population in Europe and the USA and requiring 1-3% of health-care expenditure as a result of stroke, sudden death, heart failure, unplanned hospital admissions, and other complications. Early diagnosis of atrial fibrillation, ideally before the first complication occurs, remains (...) a challenge, as shown by patients who are only diagnosed with the condition when admitted to hospital for acute cardiac decompensation or stroke. Once diagnosed, atrial fibrillation requires chronic, multidimensional management in five domains (acute management, treatment of underlying and concomitant cardiovascular conditions, stroke prevention therapy, rate control, and rhythm control). The consistent provision of these treatment options to all patients with atrial fibrillation is difficult, despite

Lancet2017

146. Arterial Hypertension, Atrial Fibrillation And Hyperaldosteronism: The Triple Trouble

Arterial Hypertension, Atrial Fibrillation And Hyperaldosteronism: The Triple Trouble 28264920 2018 01 29 2018 11 13 1524-4563 69 4 2017 04 Hypertension (Dallas, Tex. : 1979) Hypertension Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. 545-550 10.1161/HYPERTENSIONAHA.116.08956 Seccia Teresa M TM From the Clinica dell'Ipertensione Arteriosa, Department of Medicine-DIMED, University of Padua, Italy (T.M.S., B.C., G.M., M.C., G.P.R.); and Division (...) Women's Hospital, Harvard Medical School, Boston, MA (G.K.A.). gianpaolo.rossi@unipd.it. eng K24 HL103845 HL NHLBI NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review United States Hypertension 7906255 0194-911X IM Atrial Fibrillation complications physiopathology Humans Hyperaldosteronism complications physiopathology Hypertension complications physiopathology 2017 3 8 6 0 2018 1 30 6 0 2017 3 8 6 0 ppublish 28264920 HYPERTENSIONAHA

Hypertension (Dallas, Tex. : 1979)2017 Full Text: Link to full Text with Trip Pro

147. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease

Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease 28302287 2017 03 17 2017 03 17 1558-3597 69 11 2017 Mar 21 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. 1363-1371 S0735-1097(17)30344-3 10.1016/j.jacc.2016.12.038 Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist. Phase III trials (...) comparing non-vitamin K antagonist oral anticoagulants (NOACs) with warfarin excluded patients with moderate/severe mitral stenosis or mechanical heart valves, but variably included patients with other VHD and valve surgeries. This study aimed to determine relative safety and efficacy of NOACs in patients with VHD. We performed a meta-analysis of the 4 phase III AF trials of the currently available NOACs versus warfarin in patients with coexisting VHD to assess pooled estimates of relative risk (RR

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

148. Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation

Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation 28355442 2018 11 13 2380-6591 2 5 2017 May 01 JAMA cardiology JAMA Cardiol Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation. 516-523 10.1001/jamacardio.2017.0064 Accumulating evidence links inflammation and atrial fibrillation (AF). To assess whether markers of systemic and atrial inflammation are associated with incident AF in the general population. The Bruneck Study is a prospective (...) over a 20-year follow-up period in the Bruneck Study. Of the 909 participants included in the Bruneck Study, mean [SD] age was 58.8 (11.4) years and 448 (49.3%) were women. Among the 880 participants free of prevalent AF (n = 29) at baseline, 117 developed AF during the 20-year follow-up period (incidence rate, 8.2; 95% CI, 6.8-9.6 per 1000 person-years). The levels of soluble vascular cell adhesion molecule 1 (VCAM-1) and osteoprotegerin were significantly associated with incident AF (hazard ratio

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

149. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. 28355434 2017 03 29 2017 05 17 2380-6591 2 5 2017 May 01 JAMA cardiology JAMA Cardiol Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. 525-534 10.1001/jamacardio.2017.0065 The Apixaban for Reduction in Stroke and Other Thromboembolic Events (...) in Atrial Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin therapy in preventing stroke and all-cause death while causing significantly fewer major bleeds. To establish the value proposition of substituting apixiban therapy for warfarin therapy in patients with atrial fibrillation, we performed a cost-effectiveness analysis using patient-level data from the ARISTOTLE trial. To assess the cost and cost-effectiveness of apixaban therapy compared with warfarin therapy in patients

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

150. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.

Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. Importance: The risk of osteoporotic fracture with dabigatran use in patients with nonvalvular atrial fibrillation (NVAF) is unknown. Objective: To investigate the risk of osteoporotic fracture with dabigatran vs warfarin in patients with NVAF. Design, Setting, and Participants: Retrospective cohort study using a population-wide database managed by the Hong Kong

JAMA2017

151. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. Background Catheter ablation of atrial fibrillation is typically performed with uninterrupted anticoagulation with warfarin or interrupted non-vitamin K antagonist oral anticoagulant therapy. Uninterrupted anticoagulation with a non-vitamin K antagonist oral anticoagulant, such as dabigatran, may be safer; however, controlled data are lacking. We investigated the safety of uninterrupted dabigatran versus warfarin (...) in patients undergoing ablation of atrial fibrillation. Methods In this randomized, open-label, multicenter, controlled trial with blinded adjudicated end-point assessments, we randomly assigned patients scheduled for catheter ablation of paroxysmal or persistent atrial fibrillation to receive either dabigatran (150 mg twice daily) or warfarin (target international normalized ratio, 2.0 to 3.0). Ablation was performed after 4 to 8 weeks of uninterrupted anticoagulation, which was continued during

NEJM2017

152. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation.

Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. Importance: Antithrombotic therapies are known to prevent stroke for patients with atrial fibrillation (AF) but are often underused in community practice. Objectives: To examine the prevalence of patients with acute ischemic stroke with known history of AF who were not receiving guideline-recommended antithrombotic treatment before stroke and (...) to determine the association of preceding antithrombotic therapy with stroke severity and in-hospital outcomes. Design, Setting, and Participants: Retrospective observational study of 94 474 patients with acute ischemic stroke and known history of AF admitted from October 2012 through March 2015 to 1622 hospitals participating in the Get With the Guidelines-Stroke program. Exposures: Antithrombotic therapy before stroke. Main Outcomes and Measures: Stroke severity as measured by the National Institutes

JAMA2017

153. Atrial Fibrillation.

Atrial Fibrillation. This issue provides a clinical overview of atrial fibrillation, focusing on diagnosis, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions

Annals of Internal Medicine2017

154. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis Journals Library (...) An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study found that the use of novel oral anticoagulants has advantages over warfarin in patients with atrial fibrillation

NIHR HTA programme2017

155. Loop Recorder Detected High Rate of Atrial Fibrillation Recurrence after a Single Balloon- or Basket-Based Ablation of Paroxysmal Atrial Fibrillation: Results of the MACPAF Study

Loop Recorder Detected High Rate of Atrial Fibrillation Recurrence after a Single Balloon- or Basket-Based Ablation of Paroxysmal Atrial Fibrillation: Results of the MACPAF Study 28243592 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med Loop Recorder Detected High Rate of Atrial Fibrillation Recurrence after a Single Balloon- or Basket-Based Ablation of Paroxysmal Atrial Fibrillation: Results of the MACPAF Study. 4 10.3389/fcvm.2017.00004 Pulmonary vein (...) isolation (PVI) is an established approach to treat symptomatic non-permanent atrial fibrillation (AF). Detecting AF recurrence after PVI is important, if discontinuation of oral anticoagulation after ablation is considered. Patients with symptomatic paroxysmal AF were enrolled in the prospective randomized mesh ablator vs. cryoballoon pulmonary vein (PV) ablation of symptomatic paroxysmal AF study, comparing efficacy and safety of the HD Mesh Ablator ® (C.R. Bard, Lowell, MA, USA) and the Arctic Front

Frontiers in cardiovascular medicine2017 Full Text: Link to full Text with Trip Pro

156. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant. Design Propensity weighted (inverse probability of treatment weighted) nationwide (...) cohort study. Setting Individual linked data from three nationwide registries in Denmark. Participants Patients with non-valvular atrial fibrillation filling a first prescription for an oral anticoagulant from August 2011 to February 2016. Patients who filled a prescription for a standard dose non-vitamin K antagonist oral anticoagulant (novel oral anticoagulants, NOACs) were excluded. To control for baseline differences in the population, a propensity score for receipt of either of the four

BMJ2017 Full Text: Link to full Text with Trip Pro

157. Vernakalant (Brinavess) - Rapid conversion of recent onset atrial fibrillation

Vernakalant (Brinavess) - Rapid conversion of recent onset atrial fibrillation Published 13 February 2017 Statement of Advice: vernakalant (Brinavess ® ) 20mg/ml concentrate for solution for infusion (No: 1222/17) Cardiome UK Limited 13 January 2017 ADVICE: in the absence of a submission from the holder of the marketing authorisation vernakalant (Brinavess ® ) is not recommended for use within NHS Scotland. Indication under review: Rapid conversion of recent onset atrial fibrillation to sinus (...) rhythm in adults • For non-surgery patients: atrial fibrillation = 7 days duration • For post-cardiac surgery patients: atrial fibrillation = 3 days duration The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines

Scottish Medicines Consortium2017

158. Minimally invasive surgical (MIS) procedures for treatment of atrial fibrillation

Minimally invasive surgical (MIS) procedures for treatment of atrial fibrillation Minimally invasive surgical (MIS) procedures for treatment of atrial fibrillation Minimally invasive surgical (MIS) procedures for treatment of atrial fibrillation HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Minimally invasive surgical (MIS) procedures (...) for treatment of atrial fibrillation. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives Atrial fibrillation (AF) is a supraventricular, accelerated heart rhythm characterized by uncoordinated atrial activation that leads to inefficient, irregular atrial contraction. Surgical techniques for the treatment of AF can be broadly categorized into open heart procedures and minimally invasive procedures. The minimally invasive approach involves several small keyhole incisions in the intercostal

Health Technology Assessment (HTA) Database.2017

159. Laser balloon ablation for treatment of atrial fibrillation

Laser balloon ablation for treatment of atrial fibrillation Laser balloon ablation for treatment of atrial fibrillation Laser balloon ablation for treatment of atrial fibrillation HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Laser balloon ablation for treatment of atrial fibrillation. Lansdale: HAYES, Inc.. Healthcare Technology Brief (...) Publication. 2016 Authors' objectives Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, affecting an estimated 2.7 to 6.1 million individuals in the United States and 6 million individuals in Europe. Description of Technology: Minimally invasive cardiac ablation techniques for the treatment of AF involve creating linear, continuous, and transmural lesions in the atria as a means to produce scarring that disrupts erratic electrical conduction and helps regulate the heartbeat. Laser

Health Technology Assessment (HTA) Database.2017

160. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Van Brabandt H, San Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Van Brabandt H, San (...) Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C. Anticoagulants in non-valvular atrial fibrillation. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports. 2017 Authors' conclusions • International practice guidelines recommend prescribing anticoagulants to patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score ≥ 2 (for men) and score ≥ 3 (for women). For a CHA2DS2-VASc score = 0 they are best not prescribed. In patients

Health Technology Assessment (HTA) Database.2017